Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform.
Stockholm - Sweden, Sept. 09, 2024 (GLOBE NEWSWIRE) --
| Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform. Stratipath Breast is the first EU regulatory-compliant solution for risk stratification of breast cancer using AI-based precision diagnostics. This deep learning-based solution analyses digitised haematoxylin and eosin-stained histopathology images of breast cancer tissue to enable the identification of patients with increased risk of disease progression, thus providing novel decision support for clinicians in the diagnostic evaluation of breast cancer. In contrast to conventional molecular tests, AI-based risk profiling offers shorter turnaround times for results, delivers new insights at the point of diagnosis, and substantially reduces the reliance on expensive molecular testing. As a result, Stratipath Breast provides broader accessibility and benefits for a greater number of breast cancer patients. "Stratipath Breast represents a significant advancement by offering a faster and more cost-effective alternative to traditional molecular assays. By integrating with Roche’s navify® Digital Pathology enterprise software, a large number of pathology labs globally now gain rapid access to AI-based prognostic insights, all while streamlining laboratory processes and minimising costs." says Fredrik Wetterhall, CEO and co-founder of Stratipath. This collaboration between Stratipath and Roche represents a significant step forward in breast cancer diagnostics. By harnessing the power of artificial intelligence and digital pathology, the two organisations are committed to improving the lives of breast cancer patients worldwide. |
||
|
Lars Lengquist Stratipath +46 709574782 lars.lengquist.press@stratipath.com |
- 广州四维营销：会议会务全托管，让企业招商会 “落地即成交”
- 平安人寿联合复旦大学重磅发布《新纪元·新价值：迎接黄金发展期》寿险行业白皮书
- 2025亚洲国际音乐大赛新加坡总决赛颁奖典礼精彩纷呈
- 十一度蝉联保险业第一！BrandZ《最具价值中国品牌100强》发布：中国平安位列中国品牌第九
- 3岁女童总爱凑近皱眉看人，检查竟非近视，而是得了“老年病”——福州爱尔眼科
- 2025上海别墅装修公司有哪些？高性价比推荐：1299 元 /㎡享品质装修
- 千金药业：1.5亿智能车间圆满封顶 女性健康产业升级加速
- 林华寿独创道家古法疗法攻克三尸虫取得重大突破
- 新愿景，新启航！研华加速从IPC迈入边缘计算新时代
- PIK3CA基因检测助力乳腺癌精准治疗新篇章
- 伽澜健康助力黄河金三角区域医疗机构临床营养学科建设论坛圆满举办
- 立屯精神聚合力 政企共建助振兴—中国人寿财险广西分公司联合天等县开展主题党日活动
- 《StellarSugar》12强选手惊现韩国最大中餐厅：燕京大饭店
- 有梦有方向 青春正飞扬 “青春影像”校园歌手征集最终展示活动将在重庆举办
- 山东双嘉家庭教育走进历城一中：开展心理讲座赋能青春梦想